{
    "clinical_study": {
        "@rank": "52144", 
        "arm_group": [
            {
                "arm_group_label": "Normal Nicotine Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "These subject will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks."
            }, 
            {
                "arm_group_label": "Immediate Nicotine Reduction Group", 
                "arm_group_type": "Experimental", 
                "description": "This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks."
            }, 
            {
                "arm_group_label": "Gradual Nicotine Reduction Group", 
                "arm_group_type": "Experimental", 
                "description": "This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until the end up smoking the same VLNC cigarettes as the immediate reduction group."
            }
        ], 
        "brief_summary": {
            "textblock": "The main goal of this project is to compare two different approaches to reducing levels of\n      nicotine in cigarettes: an immediate reduction in nicotine content in cigarettes to\n      non-addictive levels or a gradual reduction in nicotine content in cigarettes to\n      non-addictive levels.  These two approaches will then be contrasted to a group that\n      continues to smoke cigarettes with nicotine content similar to conventional cigarettes."
        }, 
        "brief_title": "Project 2: Strategies for Reducing Nicotine Content in Cigarettes", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Immediate Nicotine Reduction Group", 
            "Gradual Nicotine Reduction Group", 
            "Normal Nicotine Control Group"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 18+\n\n          2. Daily smokers who smoke an average of at least five cigarettes per day for at least 1\n             year\n\n          3. Breath CO levels > 8 ppm (if \u2264 8 ppm, then NicAlert Strip level must indicate regular\n             smoking)\n\n        Exclusion Criteria:\n\n          1. Planned quit date in the next 30 days\n\n          2. Currently seeking treatment for smoking cessation\n\n          3. Currently using nicotine replacement therapies or other pharmacotherapies as\n             cessation aid (non-cessation intermittent use acceptable)\n\n          4. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence\n\n          5. Using other tobacco products or e-cigarettes more than 9 days in the past 30 days\n\n          6. Significant unstable medical conditions (Any significant change in a serious medical\n             condition occurring during the past 3 months including, cardiovascular disease, COPD,\n             and cancer, as determined by the licensed medical professional at each site)\n\n          7. Unstable psychiatric conditions (Any significant change in psychiatric symptoms\n             during the past 3 months as determined by the licensed medical professional at each\n             site)\n\n          8. Schizophrenia and schizoaffective disorder\n\n          9. Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or\n             discontinuation of medications) in the past 3 months that was a result of negative\n             changes in symptoms.\n\n         10. Positive toxicology screen for any of the following drugs: cocaine, opiates,\n             methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP\n\n               1. Marijuana will be tested for but will not be an exclusionary criterion.\n\n               2. Participants with valid prescriptions for opiates, benzodiazepines,\n                  barbiturates, amphetamines or methadone will not be excluded.\n\n               3. Participants failing the toxicology screen will be allowed to re-screen once.\n\n         11. Blood alcohol level > 0.01\n\n             a. Participants failing the blood alcohol screen will be allowed to re-screen once.\n\n         12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day\n             (female/male))\n\n         13. Pregnant, trying to become pregnant or breastfeeding\n\n         14. Predominant use of 'roll your own cigarettes'\n\n         15. CO reading >80 ppm\n\n         16. Systolic BP greater than or equal to 160\n\n             a. Participants failing for blood pressure will be allowed to re-screen once.\n\n         17. Diastolic BP greater than or equal to 100\n\n             a. Participants failing for blood pressure will be allowed to re-screen once.\n\n         18. Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty\n             thinking, inability to stand or walk, feeling faint)\n\n             a. Participants failing for blood pressure will be allowed to re-screen once.\n\n         19. Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty\n             thinking, inability to stand or walk, feeling faint)\n\n             a. Participants failing for blood pressure will be allowed to re-screen once.\n\n         20. Heart rate greater than or equal to 115 bpm\n\n             a. Participants failing for heart rate will be allowed to re-screen once.\n\n         21. Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty\n             thinking, inability to stand or walk, feeling faint)\n\n             a. Participants failing for heart rate will be allowed to re-screen once.\n\n         22. Indicating any suicidal ideation in the past month, suicide attempts in the past 5\n             years (if within past 5 to 10 years, requires physician approval), or score of >4 on\n             the MINI suicide subscale\n\n         23. Household member enrolled in the study concurrently.\n\n         24. Inability to independently read and comprehend the consent form and other written\n             study materials and measures because participants are required to complete parts of\n             the protocol at home independently.\n\n         25. Participated in prior study that involved reduced nicotine content cigarettes.\n\n         26. Having participated in a research study during the past three months in a study that\n             would impact baseline smoking or response to study products.\n\n         27. Currently taking the following anticonvulsant medications:\n\n               1. Phenytoin [Brand Name: Dilantin]\n\n               2. Carbamazepine [Brand Name: Tegretol, Carbatrol, Equetro, Epitol]\n\n               3. Oxcarbazepine [Brand Name: Trileptal]\n\n               4. Primidone [Brand Name: Mysoline]\n\n               5. Phenobarbital"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139930", 
            "org_study_id": "U54 DA031659-P2", 
            "secondary_id": "U54DA031659-03"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal Nicotine Control Group", 
                "Immediate Nicotine Reduction Group", 
                "Gradual Nicotine Reduction Group"
            ], 
            "description": "Participants will either smoke experimental cigarettes for a periods of 20-weeks.", 
            "intervention_name": "Smoking Spectrum Brand Cigarettes for 20 weeks.", 
            "intervention_type": "Behavioral"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "smoking", 
            "nicotine reduction"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Mayo Clinic Scottsdale"
                }, 
                "investigator": {
                    "last_name": "Scott Leischow, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "natalie.nardone@ucsf.edu", 
                    "last_name": "Natalie Nardone, Ph.D.", 
                    "phone": "415-514-1450"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California San Francisco"
                }, 
                "investigator": {
                    "last_name": "Neal Benowitz, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "melissa.conn@moffitt.org", 
                    "last_name": "Melissa Conn", 
                    "phone": "813-745-1757"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33617"
                    }, 
                    "name": "Moffitt Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David Drobes, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ccolino1@jhmi.edu", 
                    "last_name": "Cirielle Coline", 
                    "phone": "410-550-0159"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21224"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": {
                    "last_name": "Maxine Stitzer, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fkimmes@d.umn.edu", 
                    "last_name": "Farynn Kimmes", 
                    "phone": "218-726-8513"
                }, 
                "facility": {
                    "address": {
                        "city": "Duluth", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55812"
                    }, 
                    "name": "University of Minnesota Medical School Duluth"
                }, 
                "investigator": {
                    "last_name": "Mustafa al'Absi, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jense010@umn.edu", 
                    "last_name": "Joni Jensen", 
                    "phone": "612-624-5178"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Dorothy Hatsukami, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rachel.kozink@duke.edu", 
                    "last_name": "Rachel Kozink", 
                    "phone": "919-668-2963"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "Joseph McClernon, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eugene", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Oregon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Herb Severson, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "kathyt@upenn.edu", 
                    "last_name": "Kathy Tang", 
                    "phone": "215-746-7146"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Andrew Strasser, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "SNJuarez@mdanderson.org", 
                    "last_name": "Sarah Juarez", 
                    "phone": "713-745-2658"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MDAnderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Paul Cinciripini, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Project 2: Strategies for Reducing Nicotine Content in Cigarettes", 
        "overall_contact": {
            "email": "jense010@umn.edu", 
            "last_name": "Joni Jensen", 
            "phone": "612-624-5178"
        }, 
        "overall_contact_backup": {
            "email": "rld9@pitt.edu", 
            "last_name": "Rachel Denlinger", 
            "phone": "412-624-7865"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Toxicant exposure: expired air carbon monoxide", 
                "measure": "Toxicant exposure pattern", 
                "safety_issue": "No", 
                "time_frame": "20-week treatment period"
            }, 
            {
                "description": "Toxicant exposure: urine phenanthrene tetroal", 
                "measure": "Toxicant exposure pattern", 
                "safety_issue": "No", 
                "time_frame": "20-week treatment period"
            }, 
            {
                "description": "Toxicant exposure: urine mercapturic acid metabolites of a volatile organic chemical (benzene).", 
                "measure": "Toxicant exposure pattern", 
                "safety_issue": "No", 
                "time_frame": "20-week treatment period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cigarettes per day", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Nicotine exposure: total nicotine equivalents (TNE)", 
                "measure": "Nicotine exposure", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Other toxicant exposures: tobacco specific nitrosamines", 
                "measure": "Other toxicant exposure", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Effect biomarker:C-reactive protein", 
                "measure": "Effect biomarker", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Cessation rates", 
                "measure": "Cessation rates", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Measure of acceptability: retention", 
                "measure": "Measure of acceptability", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Measure of acceptability: Non-compliance to the study product", 
                "measure": "Measure of acceptability: Non-compliance", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Nicotine exposure: cotinine", 
                "measure": "Nicotine exposure", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Effect biomarker:  8-epi-PGF2\u03b1", 
                "measure": "Effect biomarker", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }, 
            {
                "description": "Effect biomarker: White blood cells", 
                "measure": "Effect biomarker", 
                "safety_issue": "No", 
                "time_frame": "End of treatment (Week 20)"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}